AnaptysBio to Present at J.P. Morgan Annual Healthcare Conference
January 08 2020 - 4:00PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation, today
announced that Hamza Suria, chief executive officer
of AnaptysBio, will present at the J.P. Morgan 38th Annual
Healthcare Conference on Wednesday, Jan. 15,
2020 at 2:30 p.m. PT at the Westin St.
Francis in San Francisco.
A webcast of the presentation will be available
through the investor section of the AnaptysBio website. A
replay of the webcast will be available for 90 days following the
event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing
first-in-class antibody product candidates focused on unmet medical
needs in inflammation. The Company’s proprietary anti-inflammatory
pipeline includes its anti-IL-33 antibody etokimab, previously
referred to as ANB020, for the treatment of moderate-to-severe
atopic dermatitis, eosinophilic asthma, and adult chronic
rhinosinusitis with nasal polyps, or CRSwNP; its anti-IL-36R
antibody ANB019 for the treatment of rare inflammatory diseases,
including generalized pustular psoriasis, or GPP, and palmoplantar
pustulosis, or PPP; and its anti-PD-1 agonist program, ANB030, and
other novel anti-inflammatory checkpoint receptor modulator
antibodies for treatment of certain autoimmune diseases where
immune checkpoint receptors are insufficiently activated.
AnaptysBio’s antibody pipeline has been developed using its
proprietary somatic hypermutation, or SHM platform, which uses in
vitro SHM for antibody discovery and is designed to replicate key
features of the human immune system to overcome the limitations of
competing antibody discovery technologies. AnaptysBio has also
developed multiple therapeutic antibodies in an immuno-oncology
partnership with TESARO, a GSK company, including an anti-PD-1
antagonist antibody (dostarlimab (TSR-042)), an anti-TIM-3
antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody
(TSR-033), and an inflammation partnership with Celgene, including
an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in
clinical development.
Contact:Eric Loumeau AnapytsBio,
Inc.858.362.6348eloumeau@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024